Bile acids move from digestion to endocrine control in the aging liver
Bile acids are no longer confined to their old role as detergents for fat absorption. In this review, they are treated as hormone-like signaling molecules with reach far beyond the gut, acting through nuclear receptors such as FXR and membrane receptors such as TGR5 to shape glucose handling, lipid metabolism, immune tone, and energy balance. In the liver, that signaling becomes especially relevant with age, when bile acid synthesis, enterohepatic circulation, hydrophobicity, microbial conversion, and receptor responsiveness all begin to shift in parallel. The result is a biologic environment in which the aging liver is exposed to a moving target: one part metabolic regulator, one part inflammatory trigger, and one part stress amplifier.
Aging does not simply reduce liver reserve. It remodels the bile acid network itself.
Aging reshapes bile acid synthesis, recycling, and receptor signaling
The central premise of the review is that bile acid biology and aging are bidirectionally linked. Age-associated changes alter the composition of the bile acid pool, the way these molecules are synthesized and recycled, and the degree to which they engage their receptors in liver and extrahepatic tissues. Those changes matter because bile acids are active signals, not passive metabolites. When receptor engagement becomes imbalanced, downstream effects spread into mitochondrial injury, endoplasmic reticulum stress, impaired autophagy, immune dysfunction, and senescence-associated secretory phenotypes.
That biology helps explain why bile acid dysregulation tracks with hepatic senescence and inflammaging. In a younger liver, the FXR-TGR5 axis helps preserve metabolic order. With aging, altered signaling can lose that protective coordination and instead reinforce injury pathways. The review frames this as a feedback loop: aging changes bile acids, and abnormal bile acids further accelerate aging-related liver damage.
Microbial biotransformation sits at the center of this loop. Gut bacteria modify bile acids into species with different receptor preferences and different biological effects. As the microbiota changes with age, bile acid signaling becomes less predictable, which adds another layer of instability to the aging liver-gut axis.
Why FXR and TGR5 matter at the bedside
FXR and TGR5 are not abstract molecular names; they are the receptors through which bile acids influence real clinical disease. FXR helps regulate bile acid synthesis and broader metabolic homeostasis, while TGR5 participates in energy regulation and immune modulation. When these receptors are activated appropriately, they can restrain metabolic dysfunction and inflammatory injury. When signaling is distorted, the liver may drift toward steatosis, fibrosis, and impaired immune surveillance.
This receptor logic provides a plausible framework for why aging-related liver diseases often share overlapping features despite different triggers. MASLD, ALD, autoimmune liver diseases, chronic hepatitis B, and HCC all sit within the scope of the review because each can be influenced by bile acid imbalance, chronic inflammation, and altered cell stress responses. The disease labels differ, but the signaling failure points overlap: mitochondrial stress, defective autophagy, and a persistent inflammatory state that is difficult to shut off.
MASLD, alcohol injury, autoimmunity, viral hepatitis, and cancer share the same signaling fault lines
In metabolic dysfunction-associated steatotic liver disease, bile acid disruption may worsen lipid accumulation and metabolic stress. In alcohol-associated liver disease, the same signaling network may intensify hepatocellular injury through inflammatory and mitochondrial pathways. Autoimmune liver diseases add another dimension, because immune regulation is already deranged and bile acid signaling may further shape the inflammatory milieu. Chronic hepatitis B and hepatocellular carcinoma extend the story into viral persistence and malignant transformation, where age-related bile acid remodeling may influence immune escape, chronic injury, and tumor-promoting biology.
The common thread is not a single disease mechanism but a shared vulnerability. Aging weakens the liver’s ability to buffer metabolic and inflammatory stress, and abnormal bile acid signaling can push that instability further. In this sense, bile acids behave less like digestive byproducts and more like a regulatory system whose malfunction reverberates across multiple liver disorders.
Gut microbiota links bile acid remodeling to inflammaging
The gut microbiota is not a side character in this review. It is a biochemical partner in bile acid metabolism. Microbial enzymes convert primary bile acids into secondary forms, changing receptor binding and biological activity. As aging alters the microbiome, those conversions can shift in ways that change the balance of beneficial and harmful signaling. The liver then receives a different hormonal message through portal circulation, and that message may reinforce chronic inflammation rather than resolve it.
This gut-liver crosstalk helps explain why age-related liver vulnerability rarely reflects a single insult. It is a composite process involving microbial ecology, bile acid chemistry, receptor signaling, and cellular stress responses. Once those layers move out of alignment, the liver becomes more susceptible to senescence and less capable of recovery after injury.
Therapeutic interest centers on the FXR-TGR5 axis, but the caveats are substantial
Targeting the BA-FXR-TGR5 axis appears attractive because it addresses a signaling system upstream of several aging-related injury pathways. The review evaluates this approach as a therapeutic opportunity in principle, while also emphasizing caveats. Bile acids are biologically potent, and their effects depend on species composition, receptor distribution, microbial context, and disease stage. A strategy that improves signaling in one setting could be neutral or harmful in another if the bile acid pool is already distorted in a different direction.
That complexity limits any simplistic therapeutic reading. Manipulating bile acid signaling is not the same as restoring normal physiology. It may help in selected aging-related liver diseases, but the review makes clear that the biology is context dependent and that receptor targeting has to account for metabolic state, inflammatory burden, and the evolving microbiota.
A new framework for aging-related liver disease
The review’s most useful contribution is conceptual. It reframes bile acids as endocrine mediators embedded in liver aging rather than as downstream products of hepatic dysfunction. Once bile acids are viewed this way, aging-related liver disease looks less like isolated pathology and more like a failure of interlocking regulatory circuits. FXR and TGR5 emerge as molecular gatekeepers, the microbiome becomes a metabolic co-regulator, and the aging liver appears as an organ exposed to cumulative signaling drift.
For clinicians and investigators, the practical implication is a shift in how liver aging is studied. The relevant questions are no longer limited to how much bile acid is present, but which species dominate, how receptor signaling changes over time, how the microbiome modifies those species, and how these patterns map onto metabolic, inflammatory, and malignant liver disease. The review does not provide a clinical trial endpoint or a treatment algorithm. It does identify a biologic axis that is broad enough to connect steatosis, hepatitis, autoimmunity, and cancer, and that scope is exactly what makes bile acid signaling so important in aging liver disease.